Laura Crawford, Ph.D., DABT, RAC-Drugs
Senior Director, Drug Development
Laura Crawford is a board-certified toxicologist and regulatory affairs professional, bringing 10 years of drug development experience to Nirogy. As Senior Director, Drug Development she oversees all nonclinical, clinical pharmacology, and regulatory aspects of drug development. Prior to joining Nirogy, Laura worked at Athenex, where she served increasing roles of responsibility, lastly as the Associate Director of Nonclinical Development where she lead the nonclinical development efforts for 5 clinical products, primarily in oncology. More recently, Laura worked as an Associate Principal Consultant at SciLucent, providing advisement on nonclinical development strategy, study execution, and regulatory support.
Laura has contributed to numerous investigational new drug applications (INDs) and new drug applications (NDAs) and was a key contributor to development of KlisyriⓇ (tirbanibulin) from early nonclinical development through FDA/EMA approval.
Laura holds a Ph.D. in Pharmacology & Molecular Therapeutics from The State University at Buffalo. She is a certified Diplomate of the American Board of Toxicology (DABT) and maintains Regulatory Affairs Certification (RAC).